100s of titles, one news app for just $10 a month.
Dive Deeper:
Guardant Health Clocks 22% Jump In Q1 Revenues, Reiterates FY22 Guidance
Guardant Health Inc's (NASDAQ:GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology…
Cigna Q1 Earnings Beat Expectations, Lifts FY22 Guidance
Cigna Corp (NYSE:CI) reports Q1 total revenues of $44.12 billion, +7.6% Y/Y, ahead of the consensus of $43.41 billion. Cigna brought in…
Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus
Inari Medical Inc's (NASDAQ:NARI) Q1 revenue was $86.8 million, up 4% sequentially and 51% Y/Y, beating the consensus of $83.61 million. The…
Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance
Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core…
One subscription that gives you access to news from hundreds of sites
BorgWarner Clocks 3% Sales Decline In Q1; Cuts FY22 Outlook
BorgWarner Inc (NYSE:BWA) reported a first-quarter FY22 sales decline of 3% year-on-year to $3.87 billion, beating the consensus of $3.71 billion. Net sales…
BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance
BioNTech SE (NASDAQ:BNTX) has reported Q1 FY22 revenues of €6.37 billion compared to €2.05 billion a year ago, mainly due to high demand…
Get all your news in one place

Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance

By Vandana Singh
  • Natera Inc (NASDAQ:NTRAgenerated Q1 revenues of $194.1 million, up 27.5% Y/Y, beating the consensus of $176.60 million.
  • Product revenues were $190.0 million, an increase of 57.8%.
  • The company processed approximately 489,300 tests, compared to approximately 348,200 tests in Q1 FY21.
  • The gross profit margin compressed to 46.8% from 56.1%, primarily due to the revenue recognition of approximately $28.6 million in the first quarter of 2021 due to the conclusion of its collaboration with Qiagen N.V (NYSE:QGEN).
  • At March 31, 2022, Natera held approximately $752.2 million in cash, cash equivalents, short-term investments, and restricted cash.
  • The company posted a Q1 EPS loss of $(1.45) compared to $(0.74) a year ago, beating the consensus of $(1.48).
  • Guidance: Natera anticipates FY22 sales of $790 million - $810 million, higher than the $770 million - $790 million expected earlier, compared to the consensus of $779.92 million.
  • 2022 gross margin to be approximately 46% to 48% of revenues
  • Price Action: NTRA shares are up 4.16% at $35.52 during the market session on the last check Friday.
What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Guardant Health Clocks 22% Jump In Q1 Revenues, Reiterates FY22 Guidance
Guardant Health Inc's (NASDAQ:GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology…
Cigna Q1 Earnings Beat Expectations, Lifts FY22 Guidance
Cigna Corp (NYSE:CI) reports Q1 total revenues of $44.12 billion, +7.6% Y/Y, ahead of the consensus of $43.41 billion. Cigna brought in…
Inari Medical Q1 Earnings Beat Street View, Lifts FY22 Sales Outlook Above Consensus
Inari Medical Inc's (NASDAQ:NARI) Q1 revenue was $86.8 million, up 4% sequentially and 51% Y/Y, beating the consensus of $83.61 million. The…
Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance
Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core…
One subscription that gives you access to news from hundreds of sites
BorgWarner Clocks 3% Sales Decline In Q1; Cuts FY22 Outlook
BorgWarner Inc (NYSE:BWA) reported a first-quarter FY22 sales decline of 3% year-on-year to $3.87 billion, beating the consensus of $3.71 billion. Net sales…
BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance
BioNTech SE (NASDAQ:BNTX) has reported Q1 FY22 revenues of €6.37 billion compared to €2.05 billion a year ago, mainly due to high demand…
Get all your news in one place